News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Avalon Pharmaceuticals (AVRX) Receives Audit Opinion Containing Going Concern Statement


4/7/2009 1:34:51 PM

GERMANTOWN, Md.--(BUSINESS WIRE)--Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced, in compliance with NASDAQ Marketplace Rule 4350(b)(1)(B), that the independent audit report included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2008 contained an unqualified audit opinion from its independent public accounting firm, Ernst & Young LLP, which included a “going concern” explanatory statement. This disclosure is required under NASDAQ rules and does not represent any change to the Company’s Annual Report on Form 10-K for the year ended December 31, 2008 which was filed on March 31, 2009 with the Securities and Exchange Commission.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES